BioWorld Science - Articles

Neurology/psychiatric

FSH-blocking antibody shows potential in obesity, Alzheimer’s models

Sep. 4, 2025

Researchers from Mount Sinai Center for Translational Medicine and Pharmacology at Icahn School of Medicine at Mount Sinai and colleagues have developed a therapeutic humanized antibody that blocks the action of follicle-stimulating hormone (FSH), a pituitary hormone previously thought to only play a role in fertility.

Neurology/psychiatric

Saniona names SAN-2668 clinical candidate for pediatric epilepsy

Sep. 4, 2025

No Comments

Saniona AB has selected SAN-2668 as a first-in-class clinical candidate for pediatric epilepsy.

Neurology/psychiatric

Aglaeapharma discovers new α2-adrenoceptor agonists

Sep. 3, 2025

Aglaeapharma Inc. has described compounds acting as α2-adrenoceptor agonists reported to be useful for the treatment of rhinitis, pain, insomnia, inflammatory disorders, glaucoma, cancer, anesthesia and acute kidney injury, among others.

Neurology/psychiatric

Aconcagua Bio divulges new calcitonin receptor and amylin receptor agonists

Sep. 3, 2025

Aconcagua Bio Inc. has synthesized calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone disease, periodontal disease, metabolic dysfunction-associated steatotic liver disease MASLD), osteogenesis imperfecta and cardiovascular disorders, among others.

Neurology/psychiatric

Shanghai Shenshi Wise Technology patents new Kv1.3 blockers

Sep. 3, 2025

Shanghai Shenshi Wise Technology Co. Ltd. has disclosed potassium voltage-gated channel subfamily A member 3 (KCNA3; Kv1.3) blockers reported to be useful for the treatment of Alzheimer’s disease, obesity, kidney fibrosis, type 2 diabetes and more.

Female scientist looking through microscope

Neurology/psychiatric

PARP7 inhibition relieves EAE by modulating type I interferon signaling

Sep. 3, 2025

No Comments

The regulation of type I interferon (IFN-1) signaling is crucial for fine-tuning the innate immune response to combat pathogens, fight cancer and prevent autoimmune diseases. Disrupted IFN-1 signaling plays a key role in autoimmune and inflammatory diseases. Therefore, understanding how IFN-1 production and signaling are regulated could reveal new approaches for treating conditions driven by this pathway.

Neurology/psychiatric

Grant supports evaluation of Neucore’s exosome platform for CMT1A

Sep. 3, 2025

No Comments

Neucore Bio Inc. has received a $350,000 STTR phase I grant from the National Center for Advancing Translational Sciences (NCATS) at the U.S. National Institutes of Health (NIH) to evaluate the company’s targeted exosome platform to deliver an RNA-based therapy to treat Charcot-Marie-Tooth disease type 1a (CMT1A).

Musculoskeletal

miR-33a/b are potential targets in muscular dystrophies: study

Sep. 3, 2025

No Comments

Researchers have identified a potential therapeutic target for muscular dystrophies, a group of genetic disorders characterized by progressive muscle weakness and degeneration. The study reveals that inhibiting the microRNA (miRNA) known as miRNA-33 can significantly improve muscle regeneration and ameliorate the dystrophic phenotype in animal models.

Parkinson's disease illustration showing neurons containing alpha-synuclein

Neurology/psychiatric

Arrowhead and Novartis sign agreement for ARO-SNCA

Sep. 3, 2025

No Comments

Arrowhead Pharmaceuticals Inc. has announced a global licensing and collaboration agreement with Novartis AG for ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy for the treatment of synucleinopathies such as Parkinson’s disease, and for additional targets.

Neurology/psychiatric

Shanghai Huilun Pharmaceutical discovers new Nav1.8 blockers

Sep. 2, 2025

Shanghai Huilun Pharmaceutical Co. Ltd. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, multiple sclerosis, Charcot-Marie-tooth disease and arrhythmia.